Product Images Maxalt

The text describes a graph (Figure 1) that displays the estimated probability of headache response over time after taking either a medication called izairptan or a placebo. The graph uses the Kapian-Meier method and shows that the probability of response increases over time. The data used for the graph comes from four outpatient trials and includes patients who did not respond to treatment within 2 hours.*

The text appears to be a description of a medical study that compares the effectiveness of MAXALT-MLT to placebo in treating headaches. The study includes graphs of the probability of obtaining headache relief over time. Patients who did not achieve relief within 2 hours or those who received additional treatment were censored in the study.*

This Kaplan-Meier plot is based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 1 and 2), for the treatment of headache with EsinatsdProtatity and Remstaton o Fescue. The plot includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose. Data was censored at 24 hours for patients not using additional treatments.*

This is a sample medication called "STAT R USA Gtnsedte" produced by Merek & Co, Inc. Each tablet contains 14.53mg of Rizatriptan Benzoate equivalent to 5mg of rizatriptan. It warns about the possibility of drowsiness and dizziness and the risk of intensification with alcohol. The lot number is 10087060, and it should be discarded after 03/13 in the year 2010. The remaining text is not available.*